IRIS
RICCIO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.238
EU - Europa 649
AS - Asia 309
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
SA - Sud America 1
Totale 2.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.227
IT - Italia 432
CN - Cina 153
VN - Vietnam 124
IE - Irlanda 57
NL - Olanda 52
CI - Costa d'Avorio 38
FI - Finlandia 35
DE - Germania 13
UA - Ucraina 13
FR - Francia 11
IN - India 11
CA - Canada 10
SE - Svezia 10
BG - Bulgaria 9
GB - Regno Unito 9
TR - Turchia 5
HK - Hong Kong 4
JP - Giappone 4
RO - Romania 4
SG - Singapore 4
CH - Svizzera 3
EU - Europa 3
IR - Iran 2
AU - Australia 1
ES - Italia 1
IL - Israele 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
Totale 2.239
Salva come PNG Salva come JPEG
Città #
Chandler 222
Napoli 129
Dong Ket 124
Ashburn 120
Millbury 82
Beijing 60
Des Moines 53
Amsterdam 50
Nanjing 42
Naples 42
Princeton 41
Lawrence 32
Boston 28
Dublin 26
Caserta 24
Wilmington 24
Washington 19
Jacksonville 13
Hebei 12
Los Angeles 11
Nanchang 10
Ottawa 10
Sciacca 10
Duncan 9
Redwood City 9
Seattle 9
Sofia 9
Jiaxing 8
Rome 7
Fairfield 6
Milan 6
Houston 5
New York 5
Riccione 5
Sesto San Giovanni 5
Tianjin 5
Woodbridge 5
Boardman 4
Bucharest 4
Hong Kong 4
Marano Di Napoli 4
Norwalk 4
Shenyang 4
Augusta 3
Baar 3
Brescia 3
Changsha 3
Istanbul 3
Maddaloni 3
Menlo Park 3
Nardò 3
Pomezia 3
San Giorgio Ionico 3
Absecon 2
Ann Arbor 2
Baronissi 2
Colorado Springs 2
Crespano Del Grappa 2
Erice 2
Formia 2
Frankfurt am Main 2
Frattamaggiore 2
Giugliano In Campania 2
Gragnano 2
Halle 2
Hangzhou 2
Jinan 2
Las Vegas 2
Milazzo 2
Ningbo 2
Perugia 2
Piano Di Sorrento 2
Pune 2
San Mateo 2
Sant'arpino 2
Stockholm 2
Tokyo 2
Abano Terme 1
Afragola 1
Altamura 1
Ardabil 1
Bologna 1
Brusciano 1
Callao 1
Casalnuovo Di Napoli 1
Casalnuovo di Napoli 1
Casoria 1
Castelfranco Veneto 1
Castelpoto 1
Cellole 1
Centrale 1
Columbus 1
Cormeilles-en-Parisis 1
Curinga 1
Eboli 1
Edison 1
Enna 1
Erftstadt 1
Ficarazzi 1
Forlì 1
Totale 1.402
Salva come PNG Salva come JPEG
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 106
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 65
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 65
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 59
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 55
Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. 53
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 52
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 52
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 50
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 48
Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients? 47
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 47
Current tissue molecular markers in colorectal cancer: A literature review 47
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 46
A strange epigastric pain. 45
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 44
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 44
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 41
Pituitary function and morphology in Fabry disease. 41
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 40
ROLE OF HFR CARTRIDGE IN THE REMOVAL OF MEDIATORS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 39
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 38
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 37
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 35
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease 35
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease 35
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 34
ADPKD and metformin: from bench to bedside 34
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 33
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 33
Optical Coherence Tomography Angiography Findings in Fabry Disease 33
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 32
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 32
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 32
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 32
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 30
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature 30
Atrial septum aneurysm: an unusual manifestation in ADPKD? 29
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 29
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 29
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 29
Immunomodulatory Effect of Continuous Venovenous Hemofiltration during Sepsis: Preliminary Data 28
Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease 28
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 28
Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? 27
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 26
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 26
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 26
Renal denervation in ADPKD: an exceptional case 25
Nutritional treatment in chronic kidney disease: the concept of nephroprotection. 24
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients 24
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 24
Fanconi syndrome with lysinuric protein intolerance 21
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 20
Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease 20
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 19
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 19
The potential use of biomarkers in predicting contrast-induced acute kidney injury. 19
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 19
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial 18
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family 18
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 18
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 18
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? 17
Therapeutic advances in ADPKD: the future awaits 17
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. 16
Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis 16
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 14
The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study 14
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 14
Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease 12
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. 12
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 11
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 11
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 10
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 10
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial 10
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 9
A pilot study of circulating microRNAs as potential biomarkers of Fabry disease 6
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 5
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin 5
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 4
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 4
The Case | A patient with autosomal dominant polycystic kidney disease with an atypical kidney magnetic resonance image 3
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 1
Totale 2.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.636
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201916 0 0 0 0 0 0 0 0 0 0 5 11
2019/2020285 86 10 8 20 5 11 4 17 34 41 32 17
2020/2021300 4 3 11 6 28 18 10 16 34 13 23 134
2021/2022450 4 0 5 4 7 11 28 18 33 52 116 172
2022/2023571 75 44 26 41 55 69 9 57 97 53 30 15
2023/2024436 23 92 41 38 35 76 6 62 15 12 36 0
Totale 2.453